IgG4-associated cholangitis can mimic hilar cholangiocarcinoma. Previously reported patients with IgG4-associated cholangitis mimicking cholangiocarcinoma had elevated serum IgG4 levels and long-segment biliary strictures. However, in the absence of other diagnostic criteria for malignancy, IgG4-associated cholangitis should remain a consideration among patients with normal serum IgG4 and a hilar mass suspicious for cholangiocarcinoma. The presence of a hilar mass and a malignant-appearing biliary stricture in two patients with normal serum IgG4 prompted further evaluation and subsequent concomitant liver and bile duct resection and reconstruction. The diagnosis of IgG4-associated cholangitis was established during the pathologic evaluation of the resected specimens. IgG4-associated cholangitis is a known imitator of hilar cholangiocarcinoma and should be considered in the differential diagnosis even among serologically IgG4-negative patients with a hilar mass prior to operative resection.
Aged ; Bile Ducts/pathology/surgery ; Cholangitis/blood/*diagnosis ; Diagnosis, Differential ; Humans ; Immunoglobulin G/*blood ; Klatskin Tumor/blood/*diagnosis ; Liver/pathology/surgery ; Male

Objective:To explore the blood loss during liposuction for secondary lymphedema of the lower extremities and to analyze the risk factors that influence the blood loss.Methods:Retrospective analysis of the clinical data of patients with secondary lymphedema of lower extremities at the Department of Lymphatic Surgery, Capital Medical University Affiliated Beijing Shijitan Hospital from January 2019 to December 2019. The following clinical indicators were correlated with the amount of blood loss, including age, body mass, body mass index (BMI), primary disease, hypertension, radiotherapy history, chemotherapy history, erysipelas history, affected extremity, duration of swelling, duration of primary disease, International Society of Lymphology(ISL) stage, time of operation, infiltration volume, fat aspiration, blood-tinged fluid solution, volume difference, preoperative hemoglobin. Pearson analysis was used for the univariate analysis of continuous variables, Spearman analysis was used for the univariate analysis of classified variables, multiple linear regression was used for multivariate analysis of continuous variables, and Logistic regression was used for the multivariate analysis of classified variables.Results:174 patients were enrolled, all females with a median age of 55 years. Univariate analysis showed that the age( r=0.17, P=0.026), the body mass( r=0.37, P<0.001), BMI( r=0.29, P<0.001), hypertension( r=0.25, P=0.001), the ISL stage( r=0.40, P<0.001), operative time( r=0.44, P<0.001), infiltration volume( r=0.53, P<0.001), fat aspiration( r=0.36, P<0.001), blood-tinged fluid solution( r=0.61, P<0.001) and volume difference( r=0.63, P<0.001) were associated with the blood loss. There was no correlation between primary disease, radiotherapy history, chemotherapy history, erysipelas history, affected extremity, duration of swelling, duration of primary disease, preoperative hemoglobin and blood loss( P>0.05). Multivariate analysis showed that hypertension ( r=0.14, P=0.012), operative time ( r=0.15, P=0.019) and volume difference ( r=0.30, P=0.001) were independent risk factors affecting blood loss. Conclusion:Hypertension, operative time and volume difference are the risk factors of blood loss during liposuction for secondary lymphedema of the lower extremities.

Objective:To handle blood loss during liposuction for secondary lymphedema of lower extremities in patients with secondary lymphedema.Methods:The clinical data of 214 patients with secondary lymphedema of the lower extremities undergoing liposuction at Department of Lymphatic Surgery, Capital Medical University Affliated Beijing Shijitan Hospital from Sep 2018 to Jan 2020 were retrospectively analyzed.Results:There were 209 females and 5 males. The average fat aspiration was (2 934.58±1 114.83) ml, the average blood loss was (986.04±425.16) ml, 117 patients were transfused, including autologous transfusion in 90 patients, 15 patients received allogeneic blood, and 12 patients received autologous plus allogeneic blood. The disease phase, operative time and fat aspiration were positively correlated with blood loss, and were independent risk factors affecting blood loss.Conclusion:Liposuction for secondary lymphedema of the lower extremity is an important factor leading to anemia.

Objective:To explore the blood loss during liposuction for secondary lymphedema of the lower extremities and to analyze the risk factors that influence the blood loss.Methods:Retrospective analysis of the clinical data of patients with secondary lymphedema of lower extremities at the Department of Lymphatic Surgery, Capital Medical University Affiliated Beijing Shijitan Hospital from January 2019 to December 2019. The following clinical indicators were correlated with the amount of blood loss, including age, body mass, body mass index (BMI), primary disease, hypertension, radiotherapy history, chemotherapy history, erysipelas history, affected extremity, duration of swelling, duration of primary disease, International Society of Lymphology(ISL) stage, time of operation, infiltration volume, fat aspiration, blood-tinged fluid solution, volume difference, preoperative hemoglobin. Pearson analysis was used for the univariate analysis of continuous variables, Spearman analysis was used for the univariate analysis of classified variables, multiple linear regression was used for multivariate analysis of continuous variables, and Logistic regression was used for the multivariate analysis of classified variables.Results:174 patients were enrolled, all females with a median age of 55 years. Univariate analysis showed that the age( r=0.17, P=0.026), the body mass( r=0.37, P<0.001), BMI( r=0.29, P<0.001), hypertension( r=0.25, P=0.001), the ISL stage( r=0.40, P<0.001), operative time( r=0.44, P<0.001), infiltration volume( r=0.53, P<0.001), fat aspiration( r=0.36, P<0.001), blood-tinged fluid solution( r=0.61, P<0.001) and volume difference( r=0.63, P<0.001) were associated with the blood loss. There was no correlation between primary disease, radiotherapy history, chemotherapy history, erysipelas history, affected extremity, duration of swelling, duration of primary disease, preoperative hemoglobin and blood loss( P>0.05). Multivariate analysis showed that hypertension ( r=0.14, P=0.012), operative time ( r=0.15, P=0.019) and volume difference ( r=0.30, P=0.001) were independent risk factors affecting blood loss. Conclusion:Hypertension, operative time and volume difference are the risk factors of blood loss during liposuction for secondary lymphedema of the lower extremities.

Objective:To evaluate the effect of imatinib on growth impairment in children with chronic myeloid leukemia (CML-CP) in the chronic phase.Methods:From July 2018 to July 2019, questionnaires were distributed to CML children aged <18 years at the time of diagnosis who were receiving imatinib for at least 3 months or to their parents in China. The height-for-age standard deviation score (HtSDS) and the difference of standard deviation integral (△HtSDS) were used to explore the change in height with imatinib therapy.Results:The data of 238 respondents were included; 138 (58.0% ) respondents were men. The median age at the first diagnosis of CML was 11.0 years (range, 1.4-17.9 years) , and 93 (39.0% ) respondents were at the prepuberty stage. At the time of completing the questionnaires, the median age was 15.0 years (range, 2.0-34.0 years) . The median duration of imatinib therapy was 28 months (range, 3-213 months) . Among all the respondents, the mean HtSDS when completing the questionnaires (-0.063±1.361) was significantly lower than that at the time of starting imatinib treatment (0.391±1.244) ( P<0.001) . Total 71.0% respondents showed growth impairment that was more common in those starting imatinib therapy at prepubertal age than in those starting at pubertal age. Multivariate analysis showed that younger at the start of imatinib therapy ( P<0.001) and longer duration of imatinib therapy ( P<0.001) were significantly associated with severe growth impairment on imatinib therapy. Conclusions:Imatinib induced growth impairment in children with CML-CP. Younger the age of initiation and longer the duration of imatinib therapy, more obvious the effect of imatinib on growth impairment.

ObjectiveTo determine the pharmacodynamic substance basis of Epimedii Folium（EF） and Epimedii Wushanensis Folium（EWF） in promoting osteogenic differentiation， and to establish a method to analyze the material basis of Chinese materia medica based on the correlation between chemical fingerprint and cellular metabolomics. MethodThe chemical fingerprints of 15 batches of EF with 4 species and 3 batches of EWF were analyzed by ultra performance liquid chromatography-quadrupole-electrostatic field orbitrap high-resolution mass spectrometry（UPLC-Q-Exactive Orbitrap-MS）， and partial least squares-discriminant analysis（PLS-DA） was used to analyze the peak areas of chemical fingerprints of samples. The effects of different samples on proliferative activity of MC3T3-E1 osteoblast precursors， as well as the activity of alkaline phosphatase（ALP） in osteoblasts were detected by cell counting kit-8（CCK-8） and enzyme-linked immunosorbent assay（ELISA）. At the same time， UPLC-quadrupole-time-of-flight mass spectrometry（UPLC-Q-TOF-MS/MS） was used to analyze the effects of different samples on the metabolomics of MC3T3-E1 cells， then metabolic peak table of osteogenic differentiation cells was constructed， and pharmacodynamic index mean Y₀ was introduced into the peak table. PLS was used to calculate mean Y₀ of each group， and the mean Y₀ was added to the peak table of chemical fingerprint to construct the correlation between chemical fingerprint and cell metabolome， the pharmacodynamic components of EF and EWF that promote bone differentiation were screened according to variable importance in the projection（VIP） value>1. The pharmacodynamic effects of EF and EWF were evaluated according to the mean Y₀ of each group. ResultThe chemical fingerprints of EF with different origins and EWF were completely separated. Compared with the blank group， the activity of MC3T3-E1 cells in EF and EWF groups was significantly increased， the activity of ALP in the Epimedium brevicornu（Gansu province）， E. koreanum and E. pubescens groups was significantly increased（P<0.05）. The results of cell metabolomics showed that the blank group and the model group had an obvious trend of separation. EF with different origins and EWF had different distance from the model group， indicating that EF with different origins and EWF had different effect on promoting osteogenic differentiation. Chemical fingerprint-cell metabolomics integration analysis screened 9 components closely related to the efficacy of EF and EWF， including diphylloside B， epimedin C， icariin， baohuoside Ⅰ， yinyanghuo B， β-anhydroicaritin， magnoflorine， cryptochlorogenic acid and quercetin. E. koreanum had the strongest effect on promoting osteogenic differentiation. ConclusionThis study determined that the material basis of EF and EWF promoting osteogenic differentiation were mostly flavonoids， alkaloids and organic acids， which provided ideas and methods for the screening of pharmacodynamic components and the prediction of therapeutic effect of Chinese materia medica.

Objective: To investigate the efficacy and safety of IA regimen which contains idarubicin (IDA) 8 mg/m², 10 mg/m² or 12 mg/m² as induction chemotherapy for adult patients with de-novo acute myeloid leukemia (AML) . Methods: A total of 1 215 newly diagnosed adult AML patients, ranging from May 2011 to March 2015 in the First Affiliated Hospital of Soochow University and other 36 clinical blood centers in China were enrolled in the multicenter, single-blind, non-randomized, clinical controlled study. To compare the response rate of complete remission (CR) , adverse events between different dose idarubicin combined with cytarabine (100 mg/m²) as induction chemotherapy in newly diagnosed patients of adult AML. Results: Of 1 207 evaluable AML patients were assigned to this analysis of CR rate. The CR rates of IDA 8 mg/m² group, IDA 10 mg/m² group and IDA 12 mg/m² group were 73.6% (215/292) , 84.1% (662/787) and 86.7% (111/128) , respectively (P<0.001) . After adjusted for age, blast ratio of bone marrow, FAB classification and risk stratification, the odds ratios (95% CI) of IDA 10 mg/m² group and IDA 12 mg/m² group were 0.49 (0.34-0.70) and 0.36 (0.18-0.71) , as compared with the IDA 8 mg/m² group (P<0.001, P=0.003) . In the intermediate and favorable groups, CR rates was 76.5% (163/213) , 86.9% (506/582) and 86.1% (68/79) in different doses of IDA (P=0.007) . Interestingly, IA regimen with IDA 10 mg/m² was the only beneficial factor affecting CR in this group after adjusted for age, blast ratio of bone marrow and FAB classification[OR=0.47 (95% CI 0.31-0.71) , P<0.001]. CR rates in adverse group was 50.0% (18/36) , 60.6% (43/71) and 81.8% (18/22) respectively (P=0.089) . However, the odds ratios (95% CI) of IDA 12 mg/m² when compared with the IDA 8 mg/m² was 0.22 (0.06-0.80) , after adjusted for age, blast ratio of bone marrow and FAB classification. The median time (days) of neutrophil count less than 0.5×10⁹/L in IDA 8 mg/m² group, IDA 10 mg/m² group and IDA 12 mg/m² group were 14 (11-18) , 15 (11-20) and 18 (14-22) , respectively (P=0.012) and of platelet count lower than 20×10⁹/L were 14 (7-17) , 15 (11-20) and 17 (15-21) , respectively (P=0.001) . The incidences of lung infection in the three groups were 9.8%, 13.5% and 25.2%, respectively (P<0.001) . Conclusions For young adult patients (aged 18-60 years) with AML in China, intensifying induction therapy with idarubicin 10 mg/m² is clinically superior to IDA 8 mg/m² and IDA 12 mg/m² in favorable intermediate AML subgroup. However, idarubicin 12 mg/m² is more suitable to adverse AML subgroup.